D

Devyser Diagnostics AB
STO:DVYSR

Watchlist Manager
Devyser Diagnostics AB
STO:DVYSR
Watchlist
Price: 136.5 SEK 1.49% Market Closed
Market Cap: 2.3B SEK
Have any thoughts about
Devyser Diagnostics AB?
Write Note

P/FCFE
Price to FCFE

-16
Current
-15.4
Median
25.2
Industry
Lower than median
Lower than industry value

Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

P/FCFE
-16
=
Market Cap
2.3B SEK
/
FCFE
-140.5m SEK
All Countries
Close
 
SE
D
Devyser Diagnostics AB
STO:DVYSR
Average P/FCFE: 30.7
Negative Multiple: -16
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -3 218 988.9
US
Abbvie Inc
NYSE:ABBV
12.7
US
Amgen Inc
NASDAQ:AMGN
24.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -89.9
US
Gilead Sciences Inc
NASDAQ:GILD
11.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -426.3
AU
CSL Ltd
ASX:CSL
80
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
24.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.6
NL
argenx SE
XBRU:ARGX
Negative Multiple: -108.4

P/FCFE Forward Multiples

Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/FCFE
N/A
2-Years Forward
P/FCFE
N/A
3-Years Forward
P/FCFE
N/A

See Also

Discover More